Navigation Links
Pros and Cons of Adaptive Designs: A Leisurely Conversation Between a Clinician and Two Statisticians, New Webinar Hosted by Xtalks
Date:12/17/2013

Toronto, Canada (PRWEB) December 17, 2013

This webinar will discuss adaptive designs for phase I, phase II and phase III clinical trials in oncology and will take the form of a debate between two statisticians trying to meet the requirements of an oncologist. The panel will include Dr. Marc Buyse, Founder and Chairman of IDDI, Dr. Tomasz Burzykowski, Vice President of Research for IDDI, and Dr. Everardo Saad, Scientific Director and Chairman for Dendrix and Senior Oncology Consultant for IDDI.

The pros and cons of various adaptive designs will be discussed. Topics will include continual reassessment methods for phase I trials, adaptive Bayesian designs for phase III trials, adaptive sample size increases and adaptive enrichment of phase III trials.

For more information on this webinar or to register, visit: http://xtalks.com/Pros-and-Cons-of-Adaptive-Designs.ashx.

To learn more about IDDI, visit http://www.iddi.com.

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year, thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit http://xtalks.com/ContactUs.ashx.

Contact:
Michelle Tran (416) 977-6555 ext 224
mtran(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/12/prweb11425544.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Adaptive Biotechnologies and Collaborators Present 16 Studies Demonstrating Clinical Significance of ImmunoSequencing at 55th Annual Meeting of the American Society for Hematology
2. Elsevier Introduces Adaptive Study Solution for Improved Learning and Memory Retention for Nursing and Health Professions
3. Adaptive Biotechnologies Publishes Gold Standard Method for Sequencing Cells of the Adaptive Immune System
4. Adaptive Biotechnologies Receives $2.53 million Phase II SBIR to Develop Test to Identify Cancer Patients at Risk of Death by Infection after Cord Blood Transplants
5. PI Releases High Power Piezo Amplifier to Drive Adaptive Structures, Fast Tool Servos, Vibration Cancellation Systems – Model E-482
6. Adaptive Biotechnologies Signs Biomarker Discovery Collaboration Agreement with Bristol-Myers Squibb
7. Adaptive Biotechnologies launches clonoSEQ, a more sensitive, accurate assay to detect minimal residual disease (MRD) in blood-based cancers.
8. “The New Health Conversation” to Premiere on PBS
9. GMO Answers Invites Consumers to Join the Online Conversation during GMO Awareness Month in October
10. Plant Biotechnology Companies Begin New Conversation about GMOs and How our Food is Grown
11. Intrinsically disordered proteins: A conversation with Rohit Pappu
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 24, 2017 , ... ZeptoMetrix ... falciparum culture panels with standard concentrations of histidine rich protein 2 (HRP2). ... range of concentrations from six different malaria strains, are intended for use by ...
(Date:1/24/2017)... ... January 23, 2017 , ... Oklahoma City based Sigma ... client for the firm’s PERFEQTA software and legacy product QC Manager 2.0. , ... dynamic team at CJBC and thrilled that they have decided to implement PERFEQTA and ...
(Date:1/24/2017)... Jan. 23, 2017 /PRNewswire/ - BioAmber Inc. (NYSE: ... an underwriting agreement with Rodman & Renshaw, a unit ... sole book running manager and representative of several underwriters, under ... firm commitment basis a minimum of 2,105,264 shares of ... purchase a minimum of 1,052,632 shares of common stock ...
(Date:1/23/2017)... Atlas Genetics Ltd., the ultra-rapid Point-Of-Care (POC) molecular ... raising $35 million from a syndicate including all Series C ... ... Genetics io® system has been completed with the successful CE ... 2016.  This new Series D equity issue will finance the ...
Breaking Biology Technology:
(Date:12/16/2016)... MIAMI , Dec. 16, 2016   ... intuitive Identity management products and solutions and a ... announced today that it is offering seamless, integrated ... Edam security entrance products. The solutions provide IdentyTech,s ... to secure their facilities from crime and theft. ...
(Date:12/15/2016)... VANCOUVER, Canada and BADEN-BADEN, Germany ... Solutions, a leading global financial services provider, today announced an ... in passive behavioural biometrics, to join forces. The partnership will ... fraud mitigation strategies in compliance with local data protection regulation. ... In ...
(Date:12/15/2016)... , Dec. 15, 2016 ... driving experience, health wellness and wellbeing (HWW), ... one in three new passenger vehicles begin ... recognition, gesture recognition, heart beat monitoring, brain ... monitoring, facial monitoring, and pulse detection. These ...
Breaking Biology News(10 mins):